Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor plus chemotherapy for relapsed/refractory AML
ChiCTR2300071651Phase 4Recruiting
- Sponsor
- Zhangzhou Municipal Hospital
- Start
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of selinexor in acute myeloid leukemia (AML), sponsored by Zhangzhou Municipal Hospital. Primary endpoint: CR/CRi rate. Started May 2023; status: recruiting.
02
Drugs
selinexor
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR2300071651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300071651.